Sofosbuvir/daclatasvir

Daclatasvir/sofosbuvir is a two-drug combination for the treatment of hepatitis C.[1] It is given as a single daily pill containing daclatasvir, the viral NS5A inhibitor and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase.[2]

Sofosbuvir/daclatasvir
Sovodak 60/400
Combination of
DaclatasvirNS5A inhibitor
SofosbuvirNS5B (RNA polymerase) inhibitor
Clinical data
Trade namesDarvoni, Sovodak
Pregnancy
category
  • US: B (No risk in non-human studies)
    Routes of
    administration    		Oral
    Legal status
    Legal status

    Society and culture

    The same combination is produced by an Iranian company under the trade name of Sovodak.[3] The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015.[4] Sovodak was approved by the Iranian Food and Drug Administration on October 2015[5] and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.[6]

    References
    1. Pol S, Corouge M, Vallet-Pichard A (2016). "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–6. doi:10.2147/HMER.S62014. PMC 4786064. PMID 27019602.
    2. "Highlights of prescribing information" (PDF). Retrieved 22 August 2016.
    3. Codrops. "Sovodak دارو". Retrieved 2019-07-17.
    4. https://clinicaltrials.gov/ct2/show/NCT02596880?term=sovodak&rank=1
    5. http://fda.gov.ir/uploads/05d8977da309fd47b21defea18d027ed.xls
    6. "Hepatitis Monthly | International Monthly Journal in the Field of Hepatology". Hepatitis Monthly. Retrieved 2019-07-17.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.